Rafael Dal-R Tenreiro

List of Publications by Citations

Source: https://exaly.com/author-pdf/2864413/rafael-dal-re-tenreiro-publications-by-citations.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

82 524 11 20 h-index g-index citations papers 102 5.32 777 5.3 L-index ext. citations avg, IF ext. papers

#	Paper	IF	Citations
82	Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?. <i>BMC Medicine</i> , 2018 , 16, 49	11.4	92
81	Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. <i>Journal of Clinical Epidemiology</i> , 2016 , 75, 100-7	5.7	39
80	Outcome reporting bias in clinical trials: why monitoring matters. <i>BMJ, The</i> , 2017 , 356, j408	5.9	38
79	Adherence to the International Committee of Medical Journal EditorsT(ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals. <i>Trials</i> , 2018 , 19, 448	2.8	31
78	Should research misconduct be criminalized?. Research Ethics, 2020, 16, 1-12	2.8	24
77	Assessment of Pragmatism in Recently Published Randomized Clinical Trials. <i>JAMA Internal Medicine</i> , 2018 , 178, 1278-1280	11.5	20
76	Prevention of selective outcome reporting: let us start from the beginning. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1283-1288	2.8	18
75	Low risk pragmatic trials do not always require participantsTinformed consent. <i>BMJ, The</i> , 2019 , 364, l10)93 9	17
74	When should re-consent of subjects participating in a clinical trial be requested? A case-oriented algorithm to assist in the decision-making process. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 83, 788-93	6.1	13
73	EditorsTand authorsTindividual conflicts of interest disclosure and journal transparency. A cross-sectional study of high-impact medical specialty journals. <i>BMJ Open</i> , 2019 , 9, e029796	3	11
72	Reasons for and time to retraction of genetics articles published between 1970 and 2018. <i>Journal of Medical Genetics</i> , 2019 , 56, 734-740	5.8	11
71	Trial participantsTrights after authorisation of COVID-19 vaccines. <i>Lancet Respiratory Medicine,the</i> , 2021 , 9, e30-e31	35.1	10
70	Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e342-e347	25.5	10
69	"Let me choose my COVID-19 vaccine". European Journal of Internal Medicine, 2021, 87, 104-105	3.9	9
68	Could phase 3 medicine trials be tagged as pragmatic? A case study: The Salford COPD trial. <i>Journal of Evaluation in Clinical Practice</i> , 2018 , 24, 258-261	2.5	9
67	Public preferences on written informed consent for low-risk pragmatic clinical trials in Spain. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1921-1931	3.8	8
66	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. <i>BMJ Evidence-Based Medicine</i> , 2020 ,	2.7	8

65	Remdesivir for COVID-19 in Europe: will it provide value for money?. <i>Lancet Respiratory Medicine,the</i> , 2021 , 9, 127-128	35.1	8
64	Articles provided insufficient information to conduct an appropriate retrospective assessment of the pragmatic/explanatory features of medicine trials with the PRECIS-2 tool. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1093-1102	2.8	7
63	Waste in COVID-19 clinical trials conducted in western Europe. <i>European Journal of Internal Medicine</i> , 2020 , 81, 91-93	3.9	7
62	Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials. JAMA - Journal of the American Medical Association, 2020 , 323, 1903-1904	27.4	6
61	The design can limit PRECIS-2 retrospective assessment of the clinical trial explanatory/pragmatic features. <i>Journal of Clinical Epidemiology</i> , 2020 , 126, 193-201	5.7	6
60	Efficacy and effectiveness: The wrong use of different terms. <i>European Journal of Internal Medicine</i> , 2018 , 54, e17-e18	3.9	5
59	A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines. <i>Journal of Clinical Epidemiology</i> , 2019 , 114, 60-71	5.7	5
58	For how long and with what relevance do genetics articles retracted due to research misconduct remain active in the scientific literature. <i>Accountability in Research</i> , 2021 , 28, 280-296	1.9	5
57	Do opinion articles attract more social attention than original research, relative to their citation counts?. <i>European Journal of Internal Medicine</i> , 2017 , 42, e27-e30	3.9	4
56	Are journals following the ICMJE recommendations complying with conflicts of interest disclosure policies. <i>European Journal of Internal Medicine</i> , 2018 , 57, e17-e19	3.9	4
55	Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label. <i>Vaccine</i> , 2021 , 39, 4029-4031	4.1	4
54	Potential predatory journals are colonizing the ICMJE recommendations list of followers. <i>Netherlands Journal of Medicine</i> , 2019 , 77, 92-96	0.5	4
53	Plan S: Funders are committed to open access to scientific publication. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13100	4.6	3
52	Leveraging Data Science for a Personalized Haemodialysis. <i>Kidney Diseases (Basel, Switzerland)</i> , 2020 , 6, 385-394	3.3	3
51	Are article's social media mentions associated to citation counts? An analysis in highly influential medical journals. <i>Revista Clinica Espanola</i> , 2018 , 218, 40-42	0.7	3
50	The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 539-54	16 ^{2.8}	3
49	Current COVID-19 vaccine trials in high-income countries: are placebo-controlled trials ethical?. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1565-1567	9.5	3
48	Who is willing to participate in low-risk pragmatic clinical trials without consent?. European Journal of Clinical Pharmacology, 2017 , 73, 1557-1563	2.8	2

47	Preregistration and publication of nonregulated intervention trials are here to stay (letter commenting Wallach et´al 2018, 93, 88-93). <i>Journal of Clinical Epidemiology</i> , 2018 , 99, 167-168	5.7	2
46	International trials in middle-income countries: different local scenarios require different ethical approaches. <i>Journal of the Royal Society of Medicine</i> , 2016 , 109, 47-51	2.3	2
45	Analysis of retracted articles on medicines administered to humans. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2179-2181	3.8	2
44	European non-commercial sponsors showed substantial variation in results reporting to the EU trial registry. <i>Journal of Clinical Epidemiology</i> , 2021 , 142, 161-170	5.7	2
43	Clinical trials: generalizability is much more than representativeness. <i>European Journal of Internal Medicine</i> , 2020 , 79, 123	3.9	2
42	Mandatory disclosure of financial interests of journals and editors. <i>BMJ, The</i> , 2020 , 370, m2872	5.9	2
41	Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults?. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2405-2406	3.8	2
40	Clinical Equipoise in COVID-19 Vaccine Candidate Trials. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 1249	9 ₂ 1@50) 2
39	Placebo-controlled trials with COVID-19 vaccines: participants first. <i>Journal of Clinical Epidemiology</i> , 2021 , 138, 211-212	5.7	2
38	Who are the Spanish sponsors of the higher number of non-commercial clinical trials with medicines and of the reporting of their results?. <i>Medicina Clūica</i> , 2019 , 153, e3-e4	1	2
37	US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine. <i>Vaccine</i> , 2021 , 39, 1180-1182	4.1	2
36	Who should be vaccinated against COVID-19 first?. <i>Medicina Claica (English Edition)</i> , 2021 , 156, 177-179	0.3	2
35	Unperceived similarities between clinical trials and quantum physics. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 192-193	3.8	1
34	Are article's social media mentions associated to citation counts? An analysis in highly influential medical journals. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la</i> , 2018 , 218, 40-42	0.5	1
33	What most influent psychiatry journals do not show. Revista De Psiquiatra Y Salud Mental, 2018, 11, 256	-257	1
32	Comparative effectiveness medicines research cannot assess efficacy. <i>Journal of Clinical Epidemiology</i> , 2017 , 92, 129	5.7	1
31	Single research ethics committee review for multinational trials is a misconception <i>Journal of the Royal Society of Medicine</i> , 2022 , 1410768211066909	2.3	1
30	Analysis of biomedical Spanish articles retracted between 1970 and 2018. <i>Medicina Claica</i> , 2020 , 154, 125-130	1	1

(2019-2020)

29	Reporting the details of consent procedures in clinical trials. <i>Journal of Clinical Epidemiology</i> , 2020 , 117, 150-151	5.7	1
28	On the semantics of clinical trials. The case of a TpragmaticTtrial in Alzheimer's disease. <i>European Journal of Neurology</i> , 2020 , 27, e14	6	1
27	COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020 , 127, 445-447	3.1	1
26	Thoughtful selection and use of scientific terms in clinical research: the case of ToragmaticTtrials. <i>Journal of Investigative Medicine</i> , 2021 , 69, 1056-1058	2.9	1
25	Being fair to participants in placebo-controlled COVID-19 vaccine trials. <i>Nature Medicine</i> , 2021 , 27, 938	50.5	1
24	When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine. <i>European Journal of Internal Medicine</i> , 2021 , 87, 1-2	3.9	1
23	Ethical concern regarding the UK PANORAMIC COVID-19 trial <i>British Journal of Clinical Pharmacology</i> , 2022 ,	3.8	1
22	Participant-funded clinical trials on rare diseases. Anales De Pediatra (English Edition), 2020, 93, 267.e1-	2674e9	O
21	Clinical Trials Transparency: Where Are We Today?. Trends in Cancer, 2018, 4, 1-3	12.5	О
20	2017, a key year on clinical trials transparency. <i>Medicina Clāica</i> , 2018 , 150, 80-81	1	O
19	It is time to include real-world effectiveness data on medicinal product labels <i>Lancet Respiratory Medicine,the</i> , 2022 ,	35.1	О
18	Ongoing non-industry-sponsored COVID-19 clinical trials in the first trimester of the pandemic: significant differences between the European and the USA approaches. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 1067-1072	3.8	Ο
17	Mandatory Coronavirus Disease 2019 Vaccine for Children?. JAMA Pediatrics, 2021, 175, 533-534	8.3	O
16	High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries <i>Travel Medicine and Infectious Disease</i> , 2022 , 102321	8.4	O
15	The need to implement non-industry COVID-19 clinical trials in non-high-income countries. <i>Journal of Global Health</i> , 2020 , 10, 010351	4.3	
14	ParticipantsTwritten informed consent in low-risk pragmatic clinical trials with medicines. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 205-210	3.8	
13	2017, a key year on clinical trials transparency. <i>Medicina Clūica (English Edition)</i> , 2018 , 150, 80-81	0.3	
12	Who are the Spanish sponsors of the higher number of non-commercial clinical trials with		

11	August 2021 and the Delta variant: is mandatory vaccination of individuals against SARS-CoV-2 acceptable?. <i>Medicina Claica (English Edition)</i> , 2022 , 158, 233-233	0.3
10	Placebo control group in COVID-19 vaccine trials: context and timing matters. <i>European Journal of Clinical Pharmacology</i> , 2021 , 78, 523	2.8
9	Changes in ongoing clinical trial protocol designs behind the scenes. <i>European Journal of Internal Medicine</i> , 2020 , 78, 32-33	3.9
8	Acceso a los resultados de los ensayos clílicos no comerciales con medicamentos realizados en Espail. <i>Revista Clinica Espanola</i> , 2021 , 222, 116-116	0.7
7	Modifications and waivers of informed consent and the Council for International Organizations of Medical Sciences guidelines. <i>Medicina Claica (English Edition)</i> , 2019 , 152, 78-79	0.3
6	Modifications and waivers of informed consent and the Council for International Organizations of Medical Sciences guidelines. <i>Medicina Clūica</i> , 2019 , 152, 78-79	1
5	Pragmatic trials, blinding, placebos, and the usefulness of the PRECIS-2 tool. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 1071-1072	2.8
4	JournalsTTOP guidelines transparency level should be disclosed. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 249-250	2.8
3	How to improve the integrity of clinical trial articles. <i>Revista De Psiquiatr Y Salud Mental (English Edition)</i> , 2018 , 11, 189-191	0.2
2	Access to the results of non-commercial clinical trials with medicines conducted in Spain. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la</i> , 2021 , 222, 116-116	0.5
1	Financial conflicts of interest in medical journals. <i>Emergencias</i> , 2018 , 30, 201-204	0.9